EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Disulfiram in liver diseases: a double-edged sword

Wanyuan Xiong, Aiping Tian, Zibing Qian, Junfeng Li, Xiaorong Mao

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-05 · 398 (5) · 4875-4889

DOI: 10.1007/s00210-024-03710-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 16.12.2024. Verfasst von Wanyuan Xiong und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Disulfiram, Alcohol Deterrents, Liver Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: The National Natural Science Foundation of China, Lanzhou Science and Technology Plan Project, Gansu Clinical Medical Research Center of Infection & Liver Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disulfiram, a synthetic drug, has historically played a significant role in the treatment of alcoholic liver disease as the first medication approved by the U.S. Food and Drug Administration for alcohol use disorders. Beyond its efficacy in inhibiting alcohol addiction and treating alcoholic liver disease, disulfiram has also demonstrated potential in managing various liver conditions, including certain metabolic liver injuries and liver cancer. As an established, cost-effective drug with well-documented synthesis methods, disulfiram holds promise for broader application in liver disease treatment. However, its clinical use is hindered by the risk of inducing pharmacologic liver injury. This potential for liver toxicity necessitates careful patient selection, monitoring, and consultation with healthcare providers, which can limit its practicality in treating patients with existing liver conditions. This review aims to analyze the multifaceted role of disulfiram in liver diseases comprehensively. By exploring its therapeutic efficacy, potential benefits, and inherent limitations, we seek to provide a balanced perspective that maximizes disulfiram's therapeutic potential while ensuring the safety and well-being of patients. This thorough examination will also highlight areas for future research, paving the way for optimized treatment protocols that incorporate disulfiram in the context of liver disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DisulfiramAlcohol DeterrentsLiver DiseasesHumansAnimalsChemical and Drug Induced Liver InjuryLiver Diseases, Alcoholic

Stichwörter der Autor:innen

DisulfiramLiver diseasesPharmacological mechanismsSide effectsTreatment

Substanzen

DisulfiramAlcohol Deterrents

Autor:innen und Institutionen

  • The First Clinical Medical College, Lanzhou University, Lanzhou, China.
  • Department of Infectious Disease, The First Hospital of Lanzhou University, No.1 Donggang West Road, Chengguan District, Lanzhou City, 730000, Gansu Province, China.
  • Institute of Infectious Diseases, Department of Liver Disease, The First Hospital of Lanzhou University, No.1 Donggang West Road, Chengguan District, Lanzhou City, 730000, Gansu Province, China. junfenglee@126.com.
  • Department of Infectious Disease, The First Hospital of Lanzhou University, No.1 Donggang West Road, Chengguan District, Lanzhou City, 730000, Gansu Province, China. maoxr@lzu.edu.cn.

Förderung

  • The National Natural Science Foundation of China
  • Lanzhou Science and Technology Plan Project
  • Gansu Clinical Medical Research Center of Infection & Liver Diseases
  • Gansu Province Education Science and Technology Innovation Program
  • FY 2021 Special Fund for Artificial Liver
  • Gansu Provincial Key R&D Program Projects

Zitieren

APA

Xiong, W., Tian, A., Qian, Z., Li, J., & Mao, X. (2025). Disulfiram in liver diseases: a double-edged sword. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(5), 4875-4889. https://doi.org/10.1007/s00210-024-03710-7

Vancouver

Xiong W, Tian A, Qian Z, Li J, Mao X. Disulfiram in liver diseases: a double-edged sword. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(5):4875-4889. doi:10.1007/s00210-024-03710-7

BibTeX
@article{Xiong2025,
  author = {Xiong, Wanyuan and Tian, Aiping and Qian, Zibing and Li, Junfeng and Mao, Xiaorong},
  title = {Disulfiram in liver diseases: a double-edged sword},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  volume = {398},
  number = {5},
  pages = {4875--4889},
  doi = {10.1007/s00210-024-03710-7}
}
Kostenlos starten →